US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

424.59

-14.1125-3.22%

Number of Gainers:- -

Number of Losers:4

Number of Flat:- -

PE:- -

High:434.55

Open:434.25

Low:423.49

Close:438.71

Volume:5.72M

Turnover:97.16M

Market Cap:9.58B

Float Cap:8.99B

Loading ...

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026

THOMSON REUTERS

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed

Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term

THOMSON REUTERS

CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?

Simply Wall St.

Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

Investors Shrug Off Good News for Heart Patients from New Meds

Editas Medicine to Participate in Upcoming Investor Conferences

Press Release: Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Editas Medicine Files $400 Million Mixed Shelf

MT Newswires Live

Editas Medicine files $400M mixed securities shelf

Editas Medicine - May Offer up to $400 Mln of Securities - SEC Filing

THOMSON REUTERS

Acrivon Therapeutics Names Michaela Levin Chief Business Officer

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

Simply Wall St.

Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/BK4556/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":424.59283,"timestamp":1789063216765,"preClose":438.70538,"halted":0,"volume":5716387,"delay":0,"changeRate":-0.032169,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-14.112549,"latestTime":"09-10 14:00:17 EDT","open":434.25467,"high":434.5457,"low":423.48727,"amount":97159803.455773,"amplitude":0.025207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.804619,"peRate":-10.111273,"turnoverRate":0.013071,"increases":0,"decrements":4,"flats":0,"marketCap":9581921312,"floatMarketCap":8987378944},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":434.5457,"amplitude":0.025207,"preClose":438.70538,"low":423.48727,"pbRate":"2.804619","latestPrice":424.59283,"volume":5716387,"delay":0,"open":434.25467,"prevYearClose":431.70972,"prevWeekClose":475.3505,"prevMonthClose":478.4385,"prevQuarterClose":517.3469,"fiveDayClose":477.7864,"twentyDayClose":447.6086,"sixtyDayClose":476.829,"secType":"PLATE","market":"US","turnoverRate":0.013071,"peRate":-10.111273,"marketCap":9581921312,"floatMarketCap":8987378944,"timestamp":1789063216765,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":0,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665775321","title":"Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665775321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665775321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862245,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency, or AATD. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LENZ","BK4556","LU1861559042.SGD","BK4139","BK4611","BEAM","BK4588","LU1861558580.USD","BK4007","BK4585","BK4539","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665290223","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665290223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665290223?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4DNXZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","BK4139","LU1861559042.SGD","BEAM","BK4611","BK4556","LU1861558580.USD","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432460","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432460","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432460?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4139","LU1861559042.SGD","BK4588","EPV","LENZ","ALT","BK4505","BK4556","BK4585","IDNA","BK4535","PRTO","BK4539","BK4599","LU1861558580.USD","BK4611","BK4007","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317069","title":"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317069?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:21","pubTimestamp":1788798066,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultrageny...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-intellia-therapeutics-ntla-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-intellia-therapeutics-ntla-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999013999.USD","SG9999015341.SGD","LU1923622614.USD","IXJ","LU1291159041.SGD","LU1989772840.SGD","LU0868494708.USD","BK4588","LU0477156953.USD","LU1093756168.USD","LU0689626769.HKD","LU0238689110.USD","LU0942090050.USD","PAWZ","LU1929549753.HKD","LU0058720904.USD","LU1941712264.USD","LU2324357040.USD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU0965509283.SGD","LU0980610538.SGD","LU0861579265.USD","LU2357627491.SGD","LU0965509010.AUD","LU0006306889.USD","LU1037948541.HKD","IE00BJJMRZ35.SGD","BK4534","LU1571399168.USD","LU1430594728.SGD","SG9999014542.SGD","LU0130517989.USD","LU1066051811.HKD","LU2461242641.AUD","LU0122379950.USD","SG9999014567.USD","IYH","LU1066051498.USD","LU0208291251.USD","LU1162221912.USD","LU2468319806.SGD","SG9999002224.SGD","IHE","SGXZ57979304.SGD","LU0265550359.USD","BK4533","LU0320765646.SGD","LU2023250843.SGD","SG9999014559.SGD","LU1037948897.HKD","VHT","BK4535","SG9999001176.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU2125909247.SGD","IE00BN8TJ469.HKD","HRTS","LU2023250504.SGD","BK4559","SG9999001176.SGD","BMED","BK4556","LU1066053197.SGD","LU1023059063.AUD","BK4550","LU0234572021.USD","LU2491050154.USD","LU0265550946.USD","FHLC","LU2125909593.SGD","LU1861559042.SGD","LU2125154935.USD","LU1066051225.USD","SG9999001440.SGD","LU1934455863.HKD","IE00BLSP4452.SGD","RARE","LU1974910355.USD","LU1917777945.USD","LU2433249047.HKD","LU2491050071.SGD","IE00B4R5TH58.HKD","FTXH","TRUH","LU1116320737.USD","LU1934455277.USD","LU1061106388.HKD","IE00BBT3K403.USD","IE00BJT1NW94.SGD","LU1069347547.HKD","SG9999015358.SGD","IE000M9KFDE8.USD","LU0124676726.USD","LU0985320562.USD","IE0009355771.USD","IE00BLSP4239.USD","LU0965508806.USD","BK4007","LU0868494617.USD","LU2106854487.HKD","LU2361045086.USD","LU1934455194.USD","LU0823416689.USD","JDOC","LU1941712348.USD","LU2125154778.USD","LU0965509101.SGD","LU0648001328.SGD","LU0266013472.USD","LU1585245621.USD","LU1201861249.SGD","LU0203345920.USD","LU0432979614.USD","IE00BSNM7G36.USD","LU1093756325.SGD","LU2361044865.SGD","LU1983299246.USD","NTLA","LU2112291526.USD","LU2089984988.USD","BK4585","LU1861558580.USD","IE0002141913.USD","LU0130102774.USD","LU0859254822.USD","LU0098860793.USD","LU1057294990.SGD","LU1989772923.USD","BK4139","LU2360032135.SGD","SG9999014575.USD","PPH","LU1035773651.USD","LU2361044949.HKD","LU2491049909.HKD","LU0106261372.USD","LU0320765489.SGD","GDOC","LU0070302665.USD","RXL","MRK","LU0211331839.USD","LU1699723380.USD","LU1989771016.USD","IE00B1BXHZ80.USD","SG9999002232.USD","BK4516","LU1116320901.HKD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354991","title":"Intellia Therapeutics Secures Major Non-Dilutive Loan Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354991","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354991?lang=en_us&edition=fundamental","pubTime":"2026-09-05 05:36","pubTimestamp":1788557781,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics ( ($NTLA) ) has provided an announcement. On September 4, 2026, Intellia Therapeutics entered into a five-year non-dilutive s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-secures-major-non-dilutive-loan-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-secures-major-non-dilutive-loan-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4535","BK4585","BK4556","BK4588","LU1861559042.SGD","NTLA","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665594033","title":"Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665594033","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665594033?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552311,"startTime":"0","endTime":"0","summary":"Intellia awards 163,100 RSUs to 41 new employees under inducement planIntellia Therapeutics awarded inducement grants to 41 new employees on Sept. 1, 2026, under its 2024 Inducement Plan.Grants cover ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLc0B329:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BCDF","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4588","BK4535","BK4112","IE00B64PRP62.GBP","SG9999014021.USD","LU1861559042.SGD","BK4556","IE00BQXX3C00.GBP","LU1861558580.USD","NTLA","LU2210149790.SGD","BK4585","SG9999014013.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665135143","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135143","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135143?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356788/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1861559042.SGD","BK4588","BK4139","NTLA","BK4556","LU1861558580.USD","LCLG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664344863","title":"Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed","url":"https://stock-news.laohu8.com/highlight/detail?id=2664344863","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664344863?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526226,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics secures $400 million senior secured term loan facility with OrbiMedIntellia Therapeutics signed a USD 400 million non-dilutive senior secured term loan facility with OrbiMed.USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5dLryB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","BK4112","BK4535","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","NDAQ","BCDF","BK4585","IE00BGHQF748.EUR","IE00BQXX3F31.USD","IE00BKPKM429.USD","LU1861558580.USD","LU0314104364.USD","BK4556","LU1861559042.SGD","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664100334","title":"Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2664100334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664100334?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0FQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4139","BK4588","NTLA","BK4556","BK4585","BK4535","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826961","title":"CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826961?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:26","pubTimestamp":1788402388,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) is back in focus after new Phase 1a durability data for CTX310, its in vivo ANGPTL3 gene editing therapy, highlighted sustained lipid reductions one year after a single infusion.\nAt a share price of $56.92, CRISPR Therapeutics has had a mixed year, with a 30 day share price return of 14.83% and a year to date share price return of 5.86%, while the 1 year total shareholder return of 7.44% suggests that momentum has been improving recently as investors react to the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","SYNB","ARKG","BK4611","LU1861559042.SGD","CRSP","SPHQ","DCF","LU1861558580.USD","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664847259","title":"Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2664847259","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664847259?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:35","pubTimestamp":1788395714,"startTime":"0","endTime":"0","summary":"20:25 EDT Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKW","SARK","ARKX","BK4544","LU1861559042.SGD","ARKF","ARKK","NTLA","ARKQ","BK4585","BK4139","BK4556","LU1861558580.USD","BK4535","BK4588","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664866385","title":"Investors Shrug Off Good News for Heart Patients from New Meds","url":"https://stock-news.laohu8.com/highlight/detail?id=2664866385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664866385?lang=en_us&edition=fundamental","pubTime":"2026-09-02 03:27","pubTimestamp":1788290820,"startTime":"0","endTime":"0","summary":"This year's run in drug stocks gained vigor from new treatments for heart attacks and strokes. Maybe some of those stocks are losing wind.At this past weekend's congress of the European Society of Car","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","LU1861559042.SGD","BK4534","BK4588","IE00BFTCPJ56.SGD","ISBC","LU0320765992.SGD","BK4533","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","BK4556","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","BK4611","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","IBBQ","TBXU","LU1861558580.USD","CRSP","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","ARKG","AMGN","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","BK4211","LU0109394709.USD","LU1057294990.SGD","BK4599","BK4581","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851760","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851760?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:00","pubTimestamp":1788267600,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354208/0/en/editas-medicine-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYNB","EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853155","title":"Press Release: Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853155","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853155?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the app","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4588","BK4505","BEAM","BK4535","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4539","LENZ","BK4611","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883078","title":"Editas Medicine Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883078?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:15","pubTimestamp":1788210958,"startTime":"0","endTime":"0","summary":"Editas Medicine  filed a registration statement Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.The filing covers debt securities, common and preferred stock, depositary shares, subscription rights, purchase contracts, warrants, and units.Net proceeds will be used for general corporate purposes, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839008","title":"Editas Medicine files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664839008?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:30","pubTimestamp":1788208221,"startTime":"0","endTime":"0","summary":"16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883801","title":"Editas Medicine - May Offer up to $400 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883801?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:26","pubTimestamp":1788207971,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003614","title":"Acrivon Therapeutics Names Michaela Levin Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003614","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003614?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:31","pubTimestamp":1788179470,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics names Michaela Levin chief business officerAcrivon Therapeutics appointed Michaela Levin as chief business officer, effective Aug. 31, 2026.Levin most recently served as vice pres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLbvKJy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BCDF","SG9999014013.SGD","BK4556","OVID","BK4588","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","ACRV","BK4112","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663457750","title":"CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2663457750","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663457750?lang=en_us&edition=fundamental","pubTime":"2026-08-30 11:25","pubTimestamp":1788060309,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics stock has had a strong shorter term recovery, yet longer term holders are still sitting on a large loss, and current valuation checks lean more toward an expensive reading than a clear bargain.\n\nThe share price is down about 52.7% over 5 years, which means many longer term investors are still under water even after more recent gains.\nFresh Phase 1a data for CTX310 presented at the ESC Congress 2026 may support confidence in CRISPR Therapeutics drug pipeline, while clinical...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-stock-may-look-rich-following-fresh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-stock-may-look-rich-following-fresh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","ARKG","SYNB","BK4556","CRSP","BK4139","LU1861558580.USD","BK4611","BK4585","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663014328","title":"Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2663014328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663014328?lang=en_us&edition=fundamental","pubTime":"2026-08-29 13:17","pubTimestamp":1787980638,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin maintained a Buy rating on Crispr Therapeutics AG yesterday. The company’s shares closed yesterday at $57.72. Acc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-buy-from-william-blair-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-buy-from-william-blair-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4588","BK4585","ARKG","BK4556","LU1861558580.USD","CRSP","BK4139","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}